Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Total Non-Current Liabilities (2022 - 2025)

Envoy Medical's Total Non-Current Liabilities history spans 4 years, with the latest figure at $14.8 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 46.92% year-over-year to $14.8 million; the TTM value through Sep 2025 reached $14.8 million, down 46.92%, while the annual FY2024 figure was $29.9 million, 268.14% up from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $14.8 million at Envoy Medical, down from $38.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $38.6 million in Q4 2022 and bottomed at $8.1 million in Q4 2023.
  • The 4-year median for Total Non-Current Liabilities is $21.1 million (2023), against an average of $23.4 million.
  • The largest annual shift saw Total Non-Current Liabilities crashed 78.97% in 2023 before it surged 268.14% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $38.6 million in 2022, then plummeted by 78.97% to $8.1 million in 2023, then soared by 268.14% to $29.9 million in 2024, then plummeted by 50.44% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Total Non-Current Liabilities are $14.8 million (Q3 2025), $38.0 million (Q2 2025), and $33.7 million (Q1 2025).